Nanomedicines are redefining pharmaceutical innovation, but their complexity demands advanced analytical solutions.
In this whitepaper, Ardena explores the analytical and regulatory challenges of characterizing nanoparticle-based drug delivery systems, and how state-of-the-art techniques like AF4-MALS-DLS can provide critical insights into particle size, morphology, stability, and drug loading.

Gain a deeper understanding of:

– How to identify and validate Critical Quality Attributes (CQAs)

– The limitations of conventional techniques like DLS

– Regulatory trends and the path toward standardization

Read the full whitepaper.

 

 

Interested in reading the full resource?

Please fill out the form to unlock the rest of the content.

Latest Resources

Our team members share deep, scientific understanding and insights into their respective fields of expertise.

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.